Sertindole: safety and tolerability profile

REFERENCES

• Moore N (2002) Higher cardiovascular mortality with sertin-dole in ADROIT: a signal not confirmed. Int J Psych Clin Pract 6 (suppl 1): S3–S9
   Google Scholar
• Haverkamp W, Eckardt L, Frederiksen K, Matz J (2002) Sertindole: cardiac electrophysiological profile. Int J Psych Clin Pract 6 (suppl 1): S11–S20
   Google Scholar
• Fleishhacker WW (1995) New drugs for the treatment of schizophrenic patients. Acta Psychiatr Scand 91 (suppl 388): 24–30.
   Google Scholar
• Goff DC, Baldessarini RJ (1993) Drug interactions with antipsychotic agents. J Clin Psychopharmacol 13 (1): 57–67.
   PubMedGoogle Scholar
• Kane JM, Honigfeld G, Singer J, et al (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45: 789–96.
   PubMed Web of Science ®Google Scholar
• Tamminga CA (1997) The promise of new drugs for schizophrenia treatment. Can J Psychiatry 42: 265–73.
   PubMed Web of Science ®Google Scholar
• Hummer M, Fleischhacker W (2000) Non-motor side effects of novel antipsychotics. Curr Opin CPNS Invest Drugs 2: 45–51.
   Google Scholar
• Kane JM (1999) Management strategies for the treatment of schizophrenia. J Clin Psychiatry 60 (suppl 12:) 13–17.
   Google Scholar
• Zimbroff DL, Kane JM, Tamminga CA, et al (1997) Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 154: 782–91.
   PubMed Web of Science ®Google Scholar
• CPMP/986/96 (1997) Points to consider, the assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products.
   Google Scholar
• H. Lundbeck A/S. Data on file.
   Google Scholar
• Kasper S, Quiner S, Pezawas L (1998) A review of the benefit: riskprofile of sertindole. Int J Psych Clin Pract 2 (suppl 2:) S59–64.
   Google Scholar
• Agelink MW, Zeit T, Baumann B, et al (2001) In vivo cardiovascular effects of the new atypical neuroleptic sertindole. Int J Psych Clin Pract 5: 33–40.
   PubMedGoogle Scholar
• Casey DE (1998) Effects of clozapine therapy in schizophrenia individuals at risk for tardive dyskinesia. J Clin Psychiatry 59 (suppl 3:) 31–7.
   Google Scholar
• Grohmann R, Ruther E, Schmidt LG (1994) Unerwünschte Wirkungen von Psychopharmaka. Ergebnisse de AMUP-Studie. Berlin: Springer.
   Google Scholar
• Hale AS (1998) A review of the safety and tolerability of sertindole. Int Clin Psychopharmacol 13 (suppl 3:) S65–70.
   Google Scholar
• Hale AS, Azorin J-M, Kasper S, et al (2000) Sertindole is associated with a low level of extrapyramidal symptoms in schizophrenic patients: results of a Phase III trial. Int J Psych Clin Pract 4: 47–54.
   PubMed Web of Science ®Google Scholar
• Meltzer HY (1999) The role of serotonin in antipsychotic drug action. Neuropsychopharmacol 21:</b>106-15S.
   Google Scholar
• Hyttel J, Nielsen JB, Nowak G (1992) The acute effect of sertindole on brain 5-HT2, D2 and a1 receptors (ex vivo radioreceptor binding studies). J Neural Transm [GenSect] 89: 61–9.
   PubMed Web of Science ®Google Scholar
• Kasper S, Tauscher J, Küfferle B, et al (1998) Sertindole and dopamine D2 receptor occupancy in comparison to risperidone, clozapine and haloperidol - a123I-IBZM SPECT study. Psychopharmacolog y 136: 367–373.
   PubMed Web of Science ®Google Scholar
• Richelson E, Souder T (2000) Binding of antipsychotic drugs to human brain receptors. Focus on newer generation compounds. Life Sciences 68: 29–39.
   PubMed Web of Science ®Google Scholar
• Nyberg S, Dencker S-J, Malm U, et al (1998) D2- and 5-HT2 receptor occupancy in high-dose neuroleptic-treated patients. Int J Neuropsychopharmcol 1: 95–101.
   PubMedGoogle Scholar
• Nyberg S, Olsson H, Nilsson U, et al (2002) Low striatal and extra-striatal D2 receptor occupancy during treatment with the atypical antipsychotic sertindole. Psychopharmacology. Online publication 14 May.
   Google Scholar
• Bymaster FP, Perry KW, Nelson DL, et al (1999) Olanzapine: a basic science update. Br J Psychiatry 174 (suppl 37:) 36–40.
   Google Scholar
• Farde L, Hall H, Ehrin E, Sedvall GC (1996) Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science 231: 258–261.
   Google Scholar
• Sanchez C, Arnt J, Dragsted N (1991) Neurochemical and in vivo pharmacological profile of sertindole, a limbic-selective compound. Drug Dev Res 22: 239–50.
   Web of Science ®Google Scholar
• Arnt J, Skarsfelt T (1998) Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18: 63–101.
   PubMed Web of Science ®Google Scholar
• Morris RGM (1984) Development of water maze procedure for studying spatial learning in the rat. J Neurosci Methods 11: 47- 60.
   PubMedGoogle Scholar
• Skarsfeldt T (1996) Differential effect of antipsychotics on place navigation of rats in the Morris water maze. A comparative study between novel and reference antipsychotics. Psychophar-macology 124: 126–33.
   PubMed Web of Science ®Google Scholar
• Hale A (2002) Sertindole -clinical efficacy profile. Int J Psch Clin Pract 6 (suppl 1): S21-S26.
   Google Scholar
• Taylor DM, McAskill R (2000) Atypical antipsychotics and weight gain - a systematic review. Acta Psychiatr Scand 101: 416–32.
   PubMed Web of Science ®Google Scholar
• Casey DE, Zorn SH (2001) The pharmacology of weight gain with antipsychotics. J Clin Psychiatry 62 (suppl 7:) 4–10.
   Google Scholar
• Hӓgg S, Joelsson L, Mjӧrndal T, et al (1998) Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry 59: 294–9.
   PubMedGoogle Scholar
• Sadock VA (2000) Normal human sexuality and sexual and gender identity disorders. In: Sadock BJ, Sadock VA (eds) Comprehensive textbook of psychiatry, 7th edition. Philadelphia: Lipincott Williams & Wilkins: 1577–662.
   Google Scholar
• Daniel DG, Wozniak P, Mack RJ, et al (1998) Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. Psychopharmacol Bul l 34: 61–9.
   PubMed Web of Science ®Google Scholar
• Kane JM (1997) Sertindole: a review of clinical efficacy. Int Clin Psychopharmacology 13 (suppl 3:) S59-64.
   Google Scholar
• Branford D, Thomson B, Muldoon C (2002) Mortality in three comparative cohorts of patients who received sertindole, risperidone and olanazapine: a hospital-based, retrospective study. Poster presented at 18th International Conference on Pharmacoepidemiology (ICPE), Edinburgh, 18-21 August.
   Google Scholar
• Sturkenboom MCJM, Picelli G, Moore N (2001) Mortality during use of sertindole and other anti-psychotics in The Netherlands and Belgium. Pharmacoepidemiol & Drug Safety 10: S1–164.
   PubMedGoogle Scholar
• Kasper S, Tauscher J, Willeit M, et al (2002) Receptor and transporter imaging-studies in schizophrenia, depression, bulimia, and Tourette’s disorder. Implications for psychophar-macology. World J Biol Psychiatry 3: 133–46.
   PubMedGoogle Scholar